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        Mendelian susceptibility to mycobacterial dis-
eases (MSMD) is a primary immunodefi  ciency 
that selectively weakens host resistance to my-
cobacteria, such as bacille Calmette-Gu  é  rin 
(BCG) vaccines and environmental mycobacte-
ria (  1, 2  ). There are six known MSMD-causing 
genes (  IL12B  ,   IL12RB1  ,   NEMO  ,   IFNGR1  , 
  IFNGR2  , and   STAT1  ), all of which are in-
volved in IFN-      –  mediated immunity. Muta-
tions in   IL12B  ,   IL12RB1  , and   NEMO   impair 
the IL-12  –  dependent production of IFN-    . In 
contrast, mutations in   IFNGR1  ,   IFNGR2  , and 
  STAT1   impair cellular responses to IFN-    . 
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  Germline mutations may cause human disease by various mechanisms. Missense and other 
in-frame mutations may be deleterious because the mutant proteins are not correctly 
targeted, do not function correctly, or both. We studied a child with mycobacterial disease 
caused by homozygosity for a novel in-frame microinsertion in   IFNGR2  . In cells transfected 
with the mutant allele, most of the interferon      receptor 2 (IFN-    R2) protein was retained 
within the cell, and that expressed on the cell surface had an abnormally high molecular 
weight (MW). The misfolding mutation was not gain-of-glycosylation, as it created no new 
N-glycosylation site. The mutant   IFNGR2   allele was null, as the patient  ’  s cells did not 
respond to IFN-    . Based on the well-established relationship between protein N-glycosyl-
ation and protein quality control processes, we tested 29 compounds affecting maturation 
by N-glycosylation in the secretory pathway. Remarkably, up to 13 of these compounds 
reduced the MW of surface-expressed mutant IFN-    R2 molecules and restored cellular 
responsiveness to IFN-    . Modifi  ers of N-glycosylation may therefore complement human 
cells carrying in-frame and misfolding, but not necessarily gain-of-glycosylation, mutations 
in genes encoding proteins subject to traffi  cking via the secretory pathway. Some of these 
compounds are available for clinical use, paving the way for clinical trials of chemical 
complementation for various human genetic traits. 
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cleotides (382  –  387) in   IFNGR2   (designated 382-387dup; 
(  Fig. 1 A  ).   This mutation is predicted to result in the du-
plication of amino acids T128 and M129 in the protein 
(WV  TM  PW  →  WV  TMTM  PW;   Fig. 1, B and C  ). This du-
plication neither creates nor deletes known consensus sites 
for posttranslational modifi  cations; in particular, it is not a 
gain-of-glycosylation mutation, as it creates no consensus 
site for N-glycosylation, unlike the previously reported 
T168N mutation in   IFNGR2   (  7  ). It was not found in 50 
and 77 unrelated healthy individuals of European and Arabian 
descent, respectively. The parents and one sibling of this 
patient are heterozygous for the mutation, which was not 
found in the other sibling. No IFN-      –  activated sequence 
(GAS)  –  binding proteins were detected in EMSAs with 
EBV-transformed B cells from P1 stimulated with IFN-     
(  Fig. 1 D  ). Similarly, no such proteins were detected in cells 
from two previously described children homozygous for 
other mutations: an in-frame 27-bp microdeletion of nucleo-
tides 663  –  689 (designated 663del27 in P2, another in-frame 
  IFNGR2   mutation) (  7  ) and the 278delAG-null frameshift 
deletion (negative control, C    , lacking IFN-    R2 expression, 
used as a negative control;   Fig. 1, C and D  ) (  6  ). IFN-    R2  –
  deficient EBV-transformed B cells homozygous for the 
278delAG allele (  6  ) were complemented by the WT allele 
but not by any of the three mutant   IFNGR2   alleles (  Fig. 1 E  ). 
Thus, P1, like P2, was homozygous for an in-frame   IFNGR2   
mutation causing complete functional IFN-    R2 defi  -
ciency (  7  ), an allele conferring a complete lack of cellular 
responses to IFN-    . 
  The 382-387dup and 663del27   IFNGR2   alleles encode 
misfolded proteins 
  We investigated the subcellular distribution of the mutant 
IFN-    R2 molecules by confocal microscopy in IFN-    R2  –
  deficient SV40-transformed fibroblasts transformed with 
WT, 382-387dup, and 663del27 IFN-    R2-eGFP con-
structs. WT IFN-    R2 was predominantly located in large 
vesicles in the cytoplasm, displaying the perinuclear distri-
bution typical of the secretory pathway. In contrast, the 
382-387dup and 663del27 IFN-    R2 molecules were dis-
seminated in smaller cytoplasmic vesicles, suggesting that 
they were abnormally traffi   cked as misfolded proteins (Fig. 
S1 A, available at http://www.jem.org/cgi/content/full/
jem.20071987/DC1). We then explored the intracellular 
traffi   cking of mutant IFN-    R2 from P1 and P2 by trans-
fecting Hek293 cells with   IFNGR2   alleles encoding V5-
tagged molecules and detecting IFN-    R2 in the lysates of 
these cells by Western blotting (  Fig. 2 A  ; and Fig. S2, A and B).   
No IFN-    R2  –  specific antibody suitable for such exper-
iments on the patients  ’   cells (or cells overexpressing 
  IFNGR2   alleles) is currently available. Both mutant proteins 
segregated into two major groups of low (    55) and high 
(    80) MW. This maturation profi  le is typical of misfolded 
proteins and results from insuffi   cient glycosylation (giving 
the lower MW) and impaired maturation upstream in the 
secretory pathway (lack of trimming of the glycan moieties, 
These genes display high levels of allelic heterogeneity, result-
ing in the defi  nition of at least 13 diff  erent disorders (  3  –  5  ). 
Four forms of IFN-    R2 defi  ciency have been described at 
the cellular level, although all known patients with IFN-    R2 
defi  ciency present only one of the three types of recessive 
MSMD. The fi  rst type was fi  rst identifi  ed in 1998 in a patient 
with complete IFN-    R2 defi  ciency, homozygous for a loss-
of-expression mutation (  6  ). Patients with complete IFN-    R2 
defi  ciency caused by surface-expressed, nonfunctional IFN-
    R2 molecules were later reported (  7, 8  ). Finally, a child 
homozygous for a hypomorphic   IFNGR2   mutation and re-
sidual IFN-     responsiveness was reported, defi  ning partial 
IFN-    R2 defi  ciency (  9  ). Dominant IFN-    R2 defi  ciency has 
not yet been reported in any symptomatic patient, but it was 
recently shown that cells from a healthy heterozygous carrier 
display weak IFN-     responses, suggesting that there may be 
patients with novel, disease-causing, dominant mutations in 
  IFNGR2   (  10  ). In any event, patients with complete IFN-
    R2 defi  ciency have a much more severe prognosis than pa-
tients with partial defi  ciency (  5  ). 
  We studied a new patient with MSMD in whom we di-
agnosed complete IFN-    R2 defi  ciency. She was homozygous 
for an in-frame   IFNGR2   mutation (382-387dup), potentially 
associated with a lack of production, a lack of surface ex-
pression, or the surface expression of nonfunctional receptors. 
Most of the mutant 382-387dup IFN-    R2 protein was of low 
molecular weight (MW) and failed to mature normally. How-
ever, mature, Endoglycosidase H (Endo-H)  –  resistant proteins 
of high MW, refl  ecting excessive N-glycosylation, were also 
found. Unlike the T168N mutation previously reported in 
  IFNGR2   ( 7, 8 ), this mutation was not gain-of-glycosylation, in 
that it did not create a new N-glycosylation site. The in-frame 
382-387dup   IFNGR2   allele thus encoded misfolded proteins 
that were abnormally targeted, abnormally N-glycosylated, or 
both. The link between protein quality control and protein 
N-glycosylation in the secretory pathway is well established (see 
Supplemental discussion, available at http://www.jem.org/
cgi/content/full/jem.20071987/DC1) (  11  –  19  ). In particular, 
glucosidases I and II, in addition to their role in the N-gly-
cosylation process, also contribute to the folding of glycopro-
teins in the endoplasmic reticulum (ER), their concomitant 
quality control by calnexin-calreticulin, and their subsequent 
traffi   cking (  12  –  18  ). ER  –  mannosidase I is also involved in gly-
coprotein folding, quality control, and traffi   cking (see   Fig. 2 B  ) 
(  12  –  18  ). The potential genetic implications of the connection 
between quality control and N-glycosylation for the chemical 
complementation of in-frame mutations leading to misfolded 
proteins have not been investigated. We investigated whether 
modifi  ers of N-glycosylation, including compounds available 
for clinical use for other purposes, could complement our 
IFN-    R2  –  defi  cient patients  ’   cells in vitro and ex vivo. 
    RESULTS AND DISCUSSION   
  A novel loss-of-function   IFNGR2   allele (382-387dup) 
  Patient 1 (P1) with MSMD was homozygous for a pre-
viously unidentifi  ed in-frame microduplication of six nu-JEM VOL. 205, August 4, 2008  1731
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in-frame loss-of-function   IFNGR2   alleles (382-387dup in P1 
and 663del27 in P2) encoded misfolded proteins that were 
abnormally N-glycosylated. 
  Maturation of the 382-387dup IFN-    R2 protein 
with NB-DNJ, castanospermine, or kifunensine 
  Glucosidases I and II are involved in the folding of glycopro-
teins in the ER, their concomitant quality control by cal-
nexin-calreticulin, and their subsequent traffi   cking (  12  –  18  ). 
ER  –  mannosidase I is also involved in glycoprotein folding, 
resulting in an abnormally high MW). In both cases, most 
proteins were of low MW and failed to mature normally, as 
shown by their sensitivity to Endo-H (  Fig. 2 A  ) (  20  ). The 
high MW of mature, Endo-H  –  resistant proteins refl  ected 
insuffi   cient maturation of the glycosylated proteins, as shown 
by their digestion with PNGase-F. Polyubiquitinylation, 
which has been reported to be responsible for the high 
MW of other misfolded proteins (  21  ), was not involved in 
this case, because digestion with PNGase-F resulted in the 
complete normalization of MW (Fig. S1 B). Thus, the two 
    Figure 1.         Clinical phenotype,   IFNGR2   genotype, and cellular phenotype of patients with MSMD.   (A) Clinical phenotypes of consanguineous 
patients. Healthy individuals are shown in white. P1, with   M. avium  , is shown in black. (B) Electrophoregram showing the mutations in exon 3 of the 
  IFNGR2   gene in P1 (382-387dup) and the WT sequence of a control. The position of the insertion is indicated by the red asterisk on the WT sequence, and 
the additional amino acids present in the mutant are shown in red. (C) Novel mutation in the   IFNGR2   gene (382-387dup). The   IFNGR2   coding  region  is 
represented by vertical bars between exons designated by Roman numerals. The leader sequence (L, 1  –  22), extracellular domain (EC,  23 – 248),  transmem-
brane domain (TM, 249  –  272), and intracellular domain (IC, 273  –  337) are indicated. Consensus sites for N-glycosylation are indicated by asterisks. Muta-
tions marked in red cause complete IFN-   R2  defi  ciency with no detectable expression of IFN-    R2 at the cell surface. The mutations indicated in blue 
cause complete IFN-   R2  defi  ciency, with detectable surface expression of a nonfunctional IFN-    R2 (reference   7  ). The mutation marked in purple causes 
partial, as opposed to complete, IFN-   R2  defi  ciency. (D) Response of EBV-transformed B cells to IFN-     and  IFN-   , as determined by EMSA analysis of 
nuclear proteins binding a GAS probe, from a positive control (C+), two patients (P1, bearing mutation 382-387dup, and P2, bearing mutation 663del27), 
and a negative control (C    , homozygous for the 278delAG   IFNGR2   allele), in response to 10  5   IU/ml  IFN-    or  IFN-    treatment for 30 min and in the ab-
sence of such treatment. (E) GAS probe  –  binding nuclear protein from EBV-transformed B cells, IFN-   R2 – defi  cient cells (278delAG) transiently transfected 
with vectors encoding WT, 278delAG, 663del27, and 382-387dup IFN-    R2 without (NS) or with 10  5   IU/ml  IFN-   , as determined by EMSA.     1732 COMPLEMENTATION OF MISFOLDING   IFNGR2   MUTATIONS   | Vogt et al. 
castanospermine had no detectable impact on WT IFN-    R2 
glycoproteins (MW of     60), but most of the mutant mole-
cules, including Endo-H  –  resistant proteins of high MW, 
displayed a shift in MW to     60 (  Fig. 2 A  ). In contrast, kifu-
nensine impaired the maturation of both WT and mutant 
molecules, which became sensitive to Endo-H (  Fig. 2 A  ). 
We assessed the surface expression of IFN-    R2 by biotinylating 
quality control, and traffi   cking (  Fig. 2 B  ) (  12  –  18  ). We there-
fore hypothesized that NB-DNJ (Zavesca) and castanosper-
mine ( 22  ), which inhibit glucosidases I and II, and kifunensine 
(  22  ), an inhibitor of ER  –  mannosidase I, might improve the 
glycosylation or traffi   cking of the nonnative IFN-    R2 mol-
ecules (  Fig. 2 B  ; and Table S1, available at http://www.jem
.org/cgi/content/full/jem.20071987/DC1). NB-DNJ and 
    Figure 2.         Biochemical properties of IFN-    R2 under various chemical treatments.   (A) Hek-293 cells were transfected with 278delAG, WT, 382-
387dup, and 663del27 IFN-    R2  –  tagged V5 constructs. They were then incubated alone or with 1   μ  M kifunensine, 1.5 mM NB-DNJ, or 2 mM castanosper-
mine for 48 h. Whole-cell extracts were generated, and left untreated or digested with Endo-H overnight. They were then subjected to SDS-PAGE and 
immunoblotting with an anti-V5 antibody. (B) Maturation of N-linked oligosaccharides: the triglucosylated polymannose oligosaccharides (GlcNac, yellow 
squares; mannose, blue circles; glucose, red circles; galactose, orange circles) transferred to the asparagine residues of proteins (green) from dolichol phos-
phate during the translation of mRNA on ribosomes. This oligosaccharide was then matured by incubation with a series of enzymes, including glucosidase I 
or II (G-I or G-II), glucosyl transferase (UGTI), erp57, calnexin (CNX), calreticulin (Crt), ER  –  mannosidase I or II (ERM-I or ERM-II), M9-mannase (M9M), Golgi  –
  mannosidase I or II (GM-I or GM-II), and glucosyl transferase I (GnT-I). Alternative pathways involving mannosidases (M*) or Golgi-endomannosidase (G-EM) 
are able to bypass the classical pathway. Some pathways for unfolded proteins lead to proteasomal or nonproteasomal proteolysis. (C) IFN-   R2 – defi  cient 
SV40-transformed fi  broblasts were transformed with the 278delAG, WT, 382-387dup, and 663del27 IFN-    R2  –  tagged V5 constructs, either without prior 
treatment or 48 h after treatment with 1.5 mM NB-DNJ, 2 mM castanospermine, or 1   μ  M kifunensine. Cell surfaces were biotinylated, and precipitates 
(IP-Strept) were analyzed by Western blotting with HRP-conjugated anti-V5 antibody. (D) IFN-   R2 – defi  cient SV40-transformed fi  broblasts were transformed 
with the 278delAG, WT, 382-387dup, or 663del27 IFN-    R2  –  tagged V5 constructs, either without prior treatment or 48 h after treatment with 1.5 mM NB-
DNJ, 2 mM castanospermine, or 1   μ  M kifunensine. Cell surfaces were biotinylated, and total extract (    ) or fl  ow through (+) from the biotinylated cells was 
analyzed by Western blotting with HRP-conjugated anti-V5 antibody. White lines indicate that intervening lanes have been spliced out.     JEM VOL. 205, August 4, 2008  1733
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pairing IFN-     binding to IFN-    R1, as the patient  ’  s cells had 
normal numbers of IFN-     binding sites of normal affi   nity 
(unpublished data). When EBV-transformed B cells from P1 
were treated with NB-DNJ, castanospermine, or kifunensine 
surface-expressed proteins in IFN-    R2  –  deficient fibro-
blasts (  6  ) transfected with various V5-tagged IFN-    R2 con-
structs, and assessing IFN-    R2 production in total extracts, 
the streptavidin-bound fraction, and fl  ow through by West-
ern blotting with a V5-specifi  c antibody (  Fig. 2, C and D  ). 
Most WT molecules with a MW   >  60 were expressed at the 
cell surface, except in the presence of kifunensine. In contrast, 
only a small fraction of mutant molecules was expressed 
at the surface, even after treatment with NB-DNJ, castanos-
permine, or kifunensine. However, after treatment with any 
of these three drugs, mutant IFN-    R2 molecules with a 
MW of     60, corresponding to the MW of WT molecules, 
appeared on the cell surface (  Fig. 2 C  ). The maturation of 
the 382-387dup and 663del27 IFN-    R2 molecules in the 
presence of NB-DNJ, castanospermine, or kifunensine thus 
resulted in the expression of a detectable fraction of receptors 
at the cell surface with a MW similar to that of WT proteins 
under the same conditions, with 663del27 molecules being 
somewhat lighter owing to the deletion of nine residues. 
It is unclear whether the surface-expressed mutant IFN-    R2 
molecules of normal MW detected in the presence of these 
compounds were generated by the maturation of IFN-    R2 
molecules of low MW that would otherwise have been re-
tained in the secretory pathway, or by the maturation of high 
MW molecules that had reached the cell surface. The time-
course experiments revealed that NB-DNJ exerted its eff  ects 
on MW after 9 h, whereas castanospermine and kifunensine 
exerted their eff  ects only after 24 h (Fig. S2, A and B). The 
exact MW of the IFN-    R2 WT molecules responding to 
IFN-     is unknown. We can only predict that the mutant 
IFN-    R2 molecules with a MW closer to that of the WT in 
the presence of glycosylation inhibitors are the most likely to 
be active. Finally, the stability and natural degradation of 
WT and mutant IFN-    R2 molecules were independent of 
the proteasome, as shown by experiments with the inhibitor 
MG132 (Fig. S3). Moreover, mutant and WT proteins be-
haved similarly in the presence of cycloheximide, a protein 
synthesis inhibitor (Fig. S3). 
  Functional complementation of the 382-387dup   IFNGR2   
allele in EBV-transformed B cells, SV40-transformed 
fi  broblasts, and blood cells 
  We therefore investigated whether cells from P1 or P2 could 
be functionally complemented by culturing EBV-transformed 
B cells with NB-DNJ, castanospermine, or kifunensine for 
16 h, and then stimulating them with IFN-     for 30 min (  Fig. 
3 A  ).   WT cells responded to IFN-     in the presence of each 
of these compounds, as shown by EMSA. Cells from a nega-
tive control (C    ) (  6  ) and cells from P2 (663del27) did not 
respond to IFN-    , even in the presence of these drugs. How-
ever, cells from P1 (382-387dup) regained responsiveness to 
IFN-     upon treatment with NB-DNJ or castanospermine. 
Surprisingly, they responded to an even greater extent when 
treated with kifunensine, with responses reaching normal 
levels (  Fig. 3 A  ). This functional complementation did not 
result from the trimming of extended IFN-    R2 glycans im-
    Figure 3.         Chemical complementation of the cellular phenotype with 
multiple drugs.   (A) Response of EBV-transformed B cells to IFN-    , as de-
termined by EMSA analysis of GAS probe  –  binding nuclear proteins from a 
positive control (C+), a negative control (C    , homozygous for the 278delAG 
  IFNGR2   allele), and two patients (P1, bearing mutation 382-387dup, and P2, 
bearing mutation 663del27) in response to 10  5   IU/ml  IFN-    treatment  for 
30 min, 16 h after incubation with 1.5 mM NB-DNJ, 2 mM castanosper-
mine, or 1   μ  M kifunensine. (B) SV40-transformed fi  broblasts from a positive 
control (C+), two patients (P1, bearing mutation 382-387dup, and P2, bear-
ing mutation 663del27), and a negative control (C    , bearing the 278delAG 
mutation) were incubated for 72 h in complete culture medium with 
(shaded histogram) or without (open histogram) 2.4   ×   10  4   IU/ml  IFN-  ,  with 
or without 1.5 mM NB-DNJ, 2 mM castanospermine, or 1 or 0.375   μ  M kifu-
nensine. They were analyzed 48 h later. The surface expression of HLA-DR 
molecules was determined by fl  ow cytometry using a specifi  c antibody.    1734 COMPLEMENTATION OF MISFOLDING   IFNGR2   MUTATIONS   | Vogt et al. 
gene with various tagged IFN-    R2 constructs (  24  –  26  ). The 
382-387dup IFN-    R2 molecules were not of normal MW 
(i.e., 60) in cells genetically defi  cient for either glucosidase II 
or glucosidase I (these cells are functionally defi  cient for both 
enzymes, as they cannot produce glucosidase II substrates; 
unpublished data). NB-DNJ and castanospermine therefore 
complemented the patient  ’  s cells by inhibiting another, as 
yet unknown, enzyme, and possibly, but not necessarily, by 
also inhibiting glucosidase I and/or II. We tested this hypo-
thesis using most of the commercially available compounds 
known to inhibit the various steps of glycosylation (  Fig. 2 B   
and Table S1). We incubated SV40-transformed fi  broblasts 
separately with each of the 29 drugs and IFN-     for 72 h. Cell-
surface HLA-DR expression was assessed by fl  ow cytometry 
(Fig. S7, available at http://www.jem.org/cgi/content/full/
jem.20071987/DC1). None of the compounds impaired the 
response of control cells or restored IFN-     responsiveness 
in fibroblasts from P2 and C    . However, 13 compounds 
restored IFN-     responsiveness in cells from P1 (Fig. S7). Six 
drugs fully complemented cells from P1 when tested at the 
recommended inhibitory concentrations (NB-DNJ, castano-
spermine, NM-DNJ, NB-DMJ, kifunensine, and 2-5-DM; 
Fig. S7). Eight other compounds had a detectable but weaker 
eff  ect. In contrast, 16 inhibitors did not complement the 
patient  ’  s cells (these compounds included tunicamycin, an 
inhibitor of N-glycosylation that blocks assembly of the 
lipid-linked oligosaccharide precursor). The inefficacy of 
australine, DMJ, and swainsonine suggested that the inhibition 
for 16 h and were stimulated with various doses of IFN-     for 
30 min, they responded to as little as 100 IU/ml IFN-     (Fig. 
S4 A, available at http://www.jem.org/cgi/content/full/
jem.20071987/DC1). We then assayed a more distal event, 
using fl  ow cytometry to test the induction of HLA-DR on 
the surface of SV40-transformed fi  broblasts (  Fig. 3 B  ). Cells 
from P1, unlike those from all other patients, responded nor-
mally to IFN-     after treatment with any of the three mole-
cules tested. Kifunensine was particularly effi   cient, as it was 
eff  ective at concentrations   <  1   μ  M and no toxicity was ob-
served, even at millimolar concentrations. In such conditions, 
fi  broblasts from P1 responded to as little as 100 IU/ml IFN-     
(Fig. S4 B). Finally, we stimulated freshly prepared PBMCs 
with live BCG, BCG plus IFN-    , or IFN-     alone, and de-
termined IL-12p40 and p70 levels by ELISA (  23  ), in the 
presence or absence of the only commercially available com-
pound, NB-DNJ (Zavesca). NB-DNJ restored the respon-
siveness to BCG plus IFN-     and to IFN-     alone with PBMCs 
from P1 (Fig. S5 and Fig. S6). Unfortunately, our patient 
died before we could test kifunensine. Thus, IFN-    R2  –  defi  cient 
cells from P1, whether immortalized lymphoid and fi  bro-
blastic cell lines or freshly prepared blood cells, were comple-
mented by modifi  ers of glycosylation. 
  Complementation of the 382-387dup   IFNGR2   allele 
with multiple modifi  ers of N-glycosylation 
  We assessed the specifi  city of enzyme inhibition by transfect-
ing human cells defective for the glucosidase I or glucosidase II 
    Figure 4.         Observation of the effects of pairs of chemical compounds.   SV40-transformed  fi  broblasts from P1, bearing mutation 382-387dup, were 
incubated for 16 h in complete culture medium supplemented with 2.4   ×   10  4   IU/ml  IFN-   . The following compounds were added, in pairs, to the culture 
medium: 1, 0.375 mM NB-DMJ; 2, 0.375 mM NB-DNJ; 3, 0.5 mM castanospermine; 4, 0.962 mM swainsonine; 5, 0.125   μ  M kifunensine; 6, 0.483 mM 
DMJ; 7, 0.338 mM australine; 8, 1.75 mM NB-DGJ; 9, 2.36 mM DNJ; 10, 3.86 mM DIM; 11, 0.15 mM mannostatin A; 12, 0.93 mM miglitol; 13, 0.37 mM 
NJ1-S; 14, 1.4 mM NM-DNJ; 15, 0.92 mM bromoconduritol (mixture of isomers); and H, distilled water. The surface expression of HLA-DR molecules was 
determined by fl  ow cytometry, using a specifi  c antibody, 72 h later.     JEM VOL. 205, August 4, 2008  1735
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  Our successful complementation of misfolding mutations 
by this novel class of chemical chaperone  –  like molecules opens 
up new avenues of research. Several modifi  ers of N-glycosyl-
ation complemented a misfolding mutation in   IFNGR2  . They 
might complement mutations in other genes. Moreover, un-
like most other previously reported chemical and pharmaco-
logical chaperones, which were active in transfected or tumor 
cells overproducing the mutant protein, these compounds 
complemented germline cells in vitro and ex vivo. Our fi  ndings 
raise hopes that chemical modifi  ers of N-glycosylation could 
be curative in some patients bearing mutations in genes en-
coding proteins subject to traffi   cking via the secretory path-
way: not only patients with gain-of-glycosylation mutations 
(  7, 8  ), but also patients bearing other types of misfolding mu-
tation. Kifunensine is a good candidate, as it has a wide win-
dow of effi   cacy without toxicity in vitro; unlike chaperones, 
which work at millimolar concentrations, it worked at below 
micromolar concentrations. Derivatives of castanospermine are 
also potentially useful (  33  ). Nevertheless, modifi  ers of gly-
cosylation should be tested carefully, as they may result in an 
acquired form of congenital disorders of glycosylation (  26  ). In 
this context, NB-DNJ (Zavesca, also known as Miglustat) is 
especially promising, as this molecule has displayed no overt 
toxicity in human clinical trials (  34  ) and is currently used in 
patients with type I Gaucher  ’  s disease because of its ability to 
inhibit glucosylceramide synthase at concentrations lower than 
those used in our study (  35  –  37  ). It will be essential to defi  ne 
the concentrations of modifi  ers of N-glycosylation that rescue 
ad hoc mutant proteins without compromising cell viability in 
vitro and in vivo. 
  MATERIALS AND METHODS 
  Aff  ected individuals.     We studied three children from three unrelated 
families with severe mycobacterial disease. All three families were consan-
guineous. P1 developed disseminated   Mycobacterium avium   disease at the 
age of 2 yr. She tested negative for HIV, CMV, and EBV in serological 
tests. Despite antimycobacterial treatment with rifamycin, moxifl  oxacin, 
hydroxychloroquine, clofazimine, and ethambutol, P1 died at the age of 
5 yr because of dissemination and uncontrolled   M. avium   infection. Neither 
of her two brothers has ever developed mycobacterial infection. P2 devel-
oped disseminated   M. avium   infection, which responded to antibiotics, at 
the age of 3 yr. He has received continuous antibiotic treatment for the last 
7 yr. P3 developed disseminated BCG vaccine infection at the age of 1 mo; 
he is now 2.5 yr old and is still on antibiotic treatment. P2 and P3 have 
been previously described (  7  ). This study was approved by the local insti-
tutional review committee (Comit  é   Consultatif de Protection des Per-
sonnes dans la Recherche Biom  é  dicale), and informed consent was 
obtained from all families. 
  Cell culture and transfection.     EBV-transformed B cells and SV40-trans-
formed fi  broblasts were cultured in RPMI 1640 supplemented with 10% heat-
inactivated bovine fetal serum (complete medium; Invitrogen). Transfection 
was performed as previously described (  7  ). 
  Cytokines, enzymes, inhibitors, and antibodies.     We used recombinant 
nonglycosylated human IFN-     (Imukin), recombinant IFN-    2b (R  &  D Sys-
tems), anti-V5 antibody (1:5,000; Invitrogen), Endo-H (New England Biolabs, 
Inc.), PNGase-F (New England Biolabs, Inc.), NB-DNJ (Sigma-Aldrich), 
castanospermine (Sigma-Aldrich), MG132 (Sigma-Aldrich), cycloheximide 
of glucosidase I, ER  –  mannosidase I, or Golgi  –  mannosidase II 
alone was insuffi   cient to complement cells from P1 (  Fig. 2 B   
and Table S1). We tested combinations of two compounds, 
each used at its minimal eff  ective concentration (  Fig. 4   and 
Table S1).   No inhibitory eff  ect was detected, but additive 
eff  ects were observed for several combinations and synergic 
eff  ects were observed in several cases (Fig. S8). Interestingly, 
no complementation was observed if australine was used with 
bromoconduritol or miglitol (  Fig. 4  ), suggesting that NB-
DNJ and castanospermine also inhibited another, as yet 
unknown, enzyme in the N-glycosylation machinery. Fur-
ther evidence to support this hypothesis is provided by the 
synergy conferred by NB-DGJ. Nonetheless, australine and 
castanospermine acted in synergy, suggesting that a potent 
and combined inhibition of glucosidase I and II is effi-
cient. Paradoxically, kifunensine and swainsonine comple-
mented the cells when used together, whereas DMJ alone did 
not (  Fig. 4  ). The complementation of cells from P1 may thus 
refl  ect the combined inhibition of several enzymes, such as 
glucosidases I and II, ER  –  mannosidase I, and other, as yet 
unknown, enzymes. 
  Concluding remarks 
  Chemical chaperones, such as DMSO and glycerol, have 
been reported to complement some cell lines in vitro, al-
beit with low specifi  city and high toxicity, preventing their 
use in clinical trials (  27  –  30  ). None of these compounds or 
the proteasome inhibitor tested (MG132) complemented the 
cell lines tested in our study (unpublished data). Curcumin 
was reported to complement delF508-CFTR in one study 
(  28  ) but not in another (  30  ), and it did not complement the 
cell lines studied in this report (unpublished data). Pharma-
cological chaperones, designed for the specifi  c complemen-
tation of target proteins, are less toxic and therefore more 
promising, but their specifi  city is not compatible with broad 
application (  29, 31, 32  ). Our report of modifi  ers of N-glyco-
sylation complementing misfolding alleles is consistent with 
the well-established role of glycans in protein folding and 
quality control in the ER (  12  –  16, 18  ). We could not assess 
whether the unfolded protein responses were triggered by 
the mutant proteins, as X-box binding protein 1 –  specifi  c anti-
bodies gave negative results in Western blots of HEK epi-
thelial cells transfected with the diff  erent constructs, whereas 
we detected X-box binding protein 1 in similar amounts in 
WT and mutant SV40  –  transformed fi  broblastic cells (unpub-
lished data). Unlike chemical and pharmacological chaperones, 
inhibitors of glycosylation do not interact directly. Instead, 
they have an indirect eff  ect via the inhibition of selected 
glycosylation enzymes. Our data identify no simple, specifi  c 
mechanism of complementation, but they do show convincingly 
that multiple modifi  ers of N-glycosylation, alone or in com-
bination, can effi   ciently complement the   IFNGR2   mutation, 
strongly suggesting that the key process involved is the modi-
fi  cation of N-glycosylation. Deciphering the exact molecular 
mechanism of action of these compounds is, however, be-
yond the scope of this report. 1736 COMPLEMENTATION OF MISFOLDING   IFNGR2   MUTATIONS   | Vogt et al. 
of EBV-transformed B cells is not altered by NB-DNJ or castanospermine 
treatment. Fig. S5 shows IFN-     responses of PBMCs from a positive con-
trol and the patient in the presence of NB-DNJ and castanospermine, as 
assessed by quantifying the production of IL-12p40 and IL-12p70. Fig. S6 
depicts IFN-     responses of PBMCs from positive controls in the presence 
of NB-DNJ and castanospermine and from negative controls, as assessed by 
quantifying the production of IL-12p40. Fig. S7 depicts IFN-     responses 
of SV40-transformed fi  broblasts from a positive control, the patient, and 
a negative control in the presence of 13 inhibitors of N-glycosylation, as 
assessed by measurements of HLA-DR induction. Fig. S8 shows examples 
of the additive and synergistic eff  ects of the diff  erent drugs on the patient  ’  s 
IFN-     response, as assessed by measuring HLA-DR induction in SV40-
transformed cells. Supplemental discussion contains information about 
N-glycosylation and quality control of proteins undergoing traffi   cking in the 
secretory pathway. Online supplemental material is available at http://www
.jem.org/cgi/content/full/jem.20071987/DC1. 
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